

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 March 2021 (25.03.2021)



(10) International Publication Number
WO 2021/055253 A2

- (51) **International Patent Classification:**
C07K 16/28 (2006.01)
- (21) **International Application Number:**
PCT/US2020/050515
- (22) **International Filing Date:**
11 September 2020 (11.09.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|--------------------------------|----|
| 62/901,364 | 17 September 2019 (17.09.2019) | US |
| 62/985,509 | 05 March 2020 (05.03.2020) | US |
| 63/047,824 | 02 July 2020 (02.07.2020) | US |
| 63/058,016 | 29 July 2020 (29.07.2020) | US |
- (71) **Applicant:** APEXIGEN, INC. [US/US]; 75 Shoreway Road, Suite C, San Carlos, California 94070 (US).
- (72) **Inventors:** FILBERT, Erin L.; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). KRISHNAN, Sushma; c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). TAN, Christine; c/o Apexigen, Inc., 75 Shoreway Road,

Suite C, San Carlos, California 94070 (US). **BAHJAT, Rena;** c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **YANG, Xiaodong;** c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US). **ALVARADO, Ryan;** c/o Apexigen, Inc., 75 Shoreway Road, Suite C, San Carlos, California 94070 (US).

(74) **Agent:** CHRISTIANSEN, William et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** ANTI-TNFR2 ANTIBODIES AND METHODS OF USE




FIG. 1

(57) **Abstract:** Provided are anti-tumor necrosis factor receptor 2 (TNFR2) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases, inflammatory and/or autoimmune diseases, and others.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*